Introduction: Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm and it can originate from the conjunctiva and/ or corneal epithelium. Since the rate of recurrence after surgical excision is high, chemotherapeutic and immunotherapeutic agents such as interferon alpha-2b (IFN α-2b) have been used for its treatment. Objective: Our objective is to describe the demographic variables of patients with OSSN treated with IFN α-2b and to describe the outcomes of its use in Mexican patients, treated between 2011 and 2017 at Instituto de Oftalmología Fundación Conde de Valenciana. Materials and Methods: This is a non-randomized retrospective interventional case series. We reviewed the fi les of patients older than 18 years, with clinical and/or histopathological diagnosis of OSSN, treated with IFN α-2b alone or in combination with surgery, with a minimum of 6 months follow-up. We studied demographic variables, such as gender, age, eye aff ected and associated risks factors; we also studied the type of therapy with interferon (topical, intralesional and/or associated with surgery), time of treatment, time of follow up, recurrences and complications. Results: A total of 39 patients were included. The mean age of diagnosis was 61 ± 16 years and OSSN was more frequent in males (64.1% of cases). Most of the cases (43.6%) had no identifi able risk factors. The mean time of IFN α-2b treatment was 5 ± 2 months, being higher in the intralesional group (6.5 months) than in the topical group (4.2 months). The clinical resolution with the use o f IFN α-2b was evidenced between 0.5 and 10 months, being achieved in 87.1% of the patients. Conclusions: The use of IFN α-2b is eff ective for the treatment of OSSN with a high success rate (87.1%) and a low incidence of relapse (5 cases), with no reported complications during follow up.
Introduction
Ocular surface squamous neoplasia (OSSN) is the most common non-pigmented ocular surface neoplasm (Shields et al, 2004) , originating from the corneal and/or conjunctival epithelium. The term ocular surface squamous neoplasia was proposed by Lee and Hirst (Lee and Hirst, 1995) , which includes dysplastic and carci nomatous lesions of the ocular surface. These can aff ect the entire thickness of the epithelium (carcinoma in situ) or cross the basement membrane and invade the stroma. Genetic factors, Ultraviolet B radiation, human papillomavirus (HPV) 16 and 18, human immunodefi ciency virus (HIV) (Mata et al., 2014) , intense smoking and exposure to petroleum products (Scott, Karp and Nuovo, 2002; Karp et al., 2010) have been associated with its etiology.
There are diff erent forms of treatment currently reported in the literature, but surgical excision with a "no touch" technique is the most accepted (Fraunfelder and Wingfi eld, 1980) . However, the rate of recurrence with this technique remains high, reported from 33% with negative surgical borders and up to 56% with positiv e surgical margins. (Tabin et al, 1997) Because of this, some adjuvant agents were introduced. Among these adjuvants are chemotherapeutic agents such as mitomycin C and 5-fl uorouracil, antiviral agents such as cidofovir, and immunotherapy agents such as interferon alpha-2b (Poothullil and Colby, 2006) . These present a non-invasive method to treat the conjunctiva, achieving a high concentration, with minimal adverse eff ects, that can be maintained or suspended according to the clinical response (de la Cruz et al., 2014) , trying to avoid the potential stem cells defi ciency associated with an extensive surgical resection .
Interferon alpha-2b (IFN α-2b) is a glycoprotein produced by leukocytes against viral infections (Fernandes et al., 2014) . It has antiviral, antimicrobial and antineoplastic activity; the latter due to the combination of antiproliferative, antiangiogenic and cytotoxic eff ects (Bracarda, Eggermont and Samuelsson, 2010) . IFN α-2b antitumor eff ect is achieved by a direct and indirect mechanism. It has a cytostatic eff ect that increases the length of cell cycle time in malign ant cells and depletes essential metabolites, slowing tumor growth. It also inhibits biosynthetic enzymes, stimulates apoptosis and the induction of antibodies against tumor cells, the expression of cell surface antigens; and tumor cytotoxicity through immune response Fernandes et al., 2014) . IFN α-2b has less adverse eff ects than mitomycin C (de la Cruz et al., 2014) and also better tolerance . It is used for the treatment of ocular malignant tumors, topically as well as via perilesional or subconjunctival injection routes (Maskin, 1994) .
The objective of this article is to describe the demographic variables of patients with OSSN treated with IFN α-2b and describe the results achieved in our patients.
Material and Methods
Study design: non-randomized retrospective interventional case series.
We searched the electronic fi le of patients with a clinical and/or histopathological diagnosis of ocul ar surface squamous neoplasia from March 2011 to March 2017. We included patients older than 18 years who gave their informed consent to be treated with IFN α-2b alone or in combination with surgery, which would have a complete fi le, photographic control and minim um follow-up of 6 months. We studied demographic variables, type of therapy with interferon (topical, intralesional and associated with surgery), time of treatment, time of followup, relapse and complications.
Type of therapy 1. Topical: the dose of IFN α-2b was 1 million international units (IU) in 1 ml. Instillation of one drops every 6 hours until 1 month after the clinical resolution of the disease. The follow-up was performed monthly until three months after clinical resolution of the lesion, then three months thereafter and then bi-annually. 2. Intralesional / subconjunctival: the dose of IFN α-2b was 3 million IU in 0.5 ml, applied once a week until the resolution of the disease. Follow-up was weekly until clinical resolution, and then it was monthly with an eventual taper to every 6 months as described in the topical treatment group. 3. Topical + Surgery: the strength and dosing of IFN α-2b were the same as in the topical group, until tumor immuno-reduction was achieved and then conventional no-touch surgery with wide margins excision (and with the application of absolute alcohol to the corneal epithelium and double row of cryotherapy to the conjunctival margin) was performed. The defect was left uncovered and no sclerectomy was performed. Follow-up was weekly, then monthly for 3 months, three months thereafter and then every 6 months. Topical interferon therapy was continued for three more months after the surgical resection.
Results
A total of 43 OSSN patients, treated with IFN α-2b were found. Four were excluded because the diagnosis was non-specifi c.
The mean age of the diagnosis was 61±16 years, with a range from 18 to 84 years. OSSN was more frequent in males, presenting in 64.1% of the cases (Table 1 and Chart 1). We identifi ed 3 IFN α-2b treatment groups: topical (N = 15) ( Figure 1) , intralesional (N = 6) ( Figure 2 ) and topical combined with surgery (N = 18) ( Figure 3 ).
The average time of treatment with IFN α-2b was 5 ± 2 months, being higher in the intralesional group (6.5 months mean use) than in the topical group (4.2 months mean use) ( Table 2 ).
There were no adverse eff ects or systemic symptoms related to treatment with IFN α-2b. There were no postoperative complications.
None of the cases treated with intralesional IFN α-2b had a recurrence. Recurrence was observed in a total of fi ve cases; two of these (5.2%) had been treated with topical IFN α-2b and three cases (7.7%) had been treated with a combination of surgery and IFN α-2b.
One of the patients treated with IFN α-2b combined with surgery was treated with orbital exenteration, and the other two patients refused any therapy. Both recurrent cases associated with topical therapy alone were given another cycle with good response, however, they were lost to follow up approximately 3 months after the beginning of the second cycle.
The clinical resolution with the use of IFN α-2b was evidenced between 0.5 and 10 months, being achieved in a total of 87.1% of all the patients. Nava-Castañeda A et al Interferon α-2b for Ocular Surface Squamous Neoplasia Nepal J Ophthalmol 2018; Vol 10 (20): 143-150 
Discussion
In our study, the average age of diagnosis of OSSN was 61±16 years, with a male predominance. This is similar to what has been described in previous studies (Kamal et al,2015) . Although most of the cases did not present identifi able risk factors, we were able to fi nd risk factors such as smoking (10.3% of cases), excessive sun exposure (18%), HPV history (20.5%), and HIV (7.6%). All these have been previously described in diff erent studies as factors associated with the etiology of OSSN Fernandes et al., 2014; Kamal et al, 2015) .
OSSN are generally treated with extensive surgical excision and cryotherapy. This may lead to limbal stem cell defi ciency and high rates of recurrence, astigmatism, and symblepharon Moon et al, 2016) . In patients with large OSSN lesions at the limbus, or recurrent lesions, this form of treatment is especially complicated . Because of this, various local chemotherapies have been studied, such as the use of IFN α-2b.
Topical ophthalmic treatment with IFN α-2b is the preferred route of administration, due to the unnecessary application of injections that can produce systemic adverse eff ects (Fernandes et al, 2014) . However, it requires a longer course of treatment to achieve full clinical resolution , needing patient cooperation and cooling of the medication Fernandes et al., 2014) . The subconjunctival / perilesional application is presented as a costeff ective treatment alternative, especially for the treatment of large tumors, in which case the topical application may not achieve suffi cient penetration Fernandes et al, 2014) .
In our series, the mean time of use of topical IFN α-2b was 4.2 months; which is similar to the 12 to 14 weeks described in the literature Nanji et al, 2014) . However, we found a greater average time of use of subconjunctival/perilesional IFN α-2b as evidenced in previous studies . This may be due to the retrospective and non-randomized nature of the cases, leaving the subconjunctival/perilesional treatment to tumors larger than those treated topically and, therefore, requiring a higher total dose and treatment time for its resolution.
Treatment with topical IFN α-2b has been reported safe and well tolerated, with no side eff ects in most cases (Boehm and Huang, 2004; Sturges et al, 2008) . Minor side eff ects are mild conjunctival hyperemia and follicular conjunctivitis (Schechter et al, 2008) , not evidenced in our series. All adverse reactions tend to resolve once the treatment is discontinued (Fernandes et al, 2014) . With the subconjunctival injection of IFN α-2b, mild systemic adverse eff ects may occur such as fl ulike symptoms, myalgias, and fever. However, these are usually mild and well tolerated . No cases of death or carcinogenic side eff ects have been reported with the ocular use of IFN medication (Fernandes et al, 2014) .
In our series, there was no evidence of adverse eff ects to the drug in its diff erent modalities of application.
A recurrence rate of 5.1% was observed in cases treated with topical IFN α-2b alone, with an average follow-up of 17.8 months.
The recurrence rates reported in the literature for this treatment modality range from 0% to 17% depending on the follow-up time (Nanji et al, 2014) . In our study, there were no cases of recurrence with subconjunctival/perilesional IFN α-2b treatment at 15.2 months of followup. This is lower than that reported by Nanji et al (2014) a recurrence rate of 7.7% at 17.5 months of average follow-up time in our study.
We demonstrated a success rate of 87.1% in our patients treated with IFN α-2b. This is concordant with previous studies Nanji et al, 2014; Galor et al, 2010; Galor et al, 2015) .
These results should be interpreted considering the limitations of our study. Largely due to it being a retrospective study, it has selection biases since more aggressive treatments were indicated to lesions with clinically greater extension. Therefore, it would be interesting to know the evolution of the disease with these three forms of treatment compared to conventional surgical treatment in a prospective way.
Conclusions
The use of IFN α-2b is eff ective for the treatment of ocular surface squamous neoplasia since a high success rate (87.1%) was found with a low incidence of recurrence (5 patients), with no complications reported during the follow-up period. It is a viable alternative to conventional treatment since it provides immune-reduction of the tumor, allows synergy with the surgical treatment, and can even be used as a monotherapy in some cases as well.
